Clene Inc. (NASDAQ:CLNN – Get Rating) Director David J. Matlin acquired 35,000 shares of Clene stock in a transaction on Friday, May 27th. The shares were purchased at an average price of $2.27 per share, for a total transaction of $79,450.00. Following the completion of the purchase, the director now directly owns 2,061,106 shares of the company’s stock, valued at $4,678,710.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of CLNN stock traded up $0.07 during trading hours on Friday, hitting $2.28. 156,462 shares of the company were exchanged, compared to its average volume of 116,247. The firm has a market cap of $144.23 million, a P/E ratio of 9.61 and a beta of 0.37. Clene Inc. has a fifty-two week low of $1.93 and a fifty-two week high of $17.82. The company has a debt-to-equity ratio of 9.64, a quick ratio of 7.76 and a current ratio of 7.77. The company has a 50 day simple moving average of $2.88 and a two-hundred day simple moving average of $3.47.
Clene (NASDAQ:CLNN – Get Rating) last posted its quarterly earnings results on Friday, March 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.14 million. As a group, sell-side analysts expect that Clene Inc. will post -0.72 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp lifted its position in Clene by 126.7% in the 4th quarter. State Street Corp now owns 883,258 shares of the company’s stock worth $3,621,000 after buying an additional 493,581 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of Clene during the fourth quarter valued at approximately $1,106,000. BlackRock Inc. grew its stake in Clene by 7.5% in the fourth quarter. BlackRock Inc. now owns 1,145,686 shares of the company’s stock worth $4,697,000 after purchasing an additional 79,960 shares during the period. Morgan Jess S & Co. Inc. grew its stake in Clene by 193.3% in the first quarter. Morgan Jess S & Co. Inc. now owns 87,250 shares of the company’s stock worth $344,000 after purchasing an additional 57,500 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Clene in the fourth quarter worth $159,000. Institutional investors own 23.07% of the company’s stock.
Clene Company Profile (Get Rating)
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
- Get a free copy of the StockNews.com research report on Clene (CLNN)
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.